NAV

CB-1158

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
CB-1158
DrugBank Accession Number
DB15286
Background

CB-1158 is under investigation in clinical trial NCT03910530 (A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors).

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 287.12
Monoisotopic: 287.165251
Chemical Formula
C11H22BN3O5
Synonyms
  • INCB001158
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
IFD73D535A
CAS number
2095732-06-0
InChI Key
ZZJLMZYUGLJBSO-LAEOZQHASA-N
InChI
InChI=1S/C11H22BN3O5/c1-7(13)9(16)15-5-8(3-2-4-12(19)20)11(14,6-15)10(17)18/h7-8,19-20H,2-6,13-14H2,1H3,(H,17,18)/t7-,8-,11-/m0/s1
IUPAC Name
(3R,4S)-3-amino-1-[(2S)-2-aminopropanoyl]-4-[3-(dihydroxyboranyl)propyl]pyrrolidine-3-carboxylic acid
SMILES
C[C@H](N)C(=O)N1C[C@H](CCCB(O)O)[C@@](N)(C1)C(O)=O

References

General References
Not Available
ChemSpider
72379905

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdvanced Solid Tumors / Metastatic Solid Neoplasm1
1, 2CompletedTreatmentBile Duct Cancer / Colorectal Cancer / Endometrial Cancer / Gastroesophageal Cancer (GC) / Ovarian Cancer / Solid Tumors1
1, 2CompletedTreatmentBladder Cancer / Colorectal Cancer / Gastric Cancer / Head And Neck Cancer / Lung Cancer / Mesothelioma / Metastatic Cancer / Renal Cell Carcinoma (RCC) / Solid Tumors / Urothelial Cancer1
1, 2TerminatedTreatmentRelapsed/Refractory Multiple Myeloma (RRMM)1
1, 2TerminatedTreatmentSolid Tumors1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.82 mg/mLALOGPS
logP-2.8ALOGPS
logP-5.2Chemaxon
logS-1.6ALOGPS
pKa (Strongest Acidic)1.99Chemaxon
pKa (Strongest Basic)8.69Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count5Chemaxon
Polar Surface Area150.11 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity66.88 m3·mol-1Chemaxon
Polarizability29.93 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0072-0490000000-5f64a2da58a65ec2fe8e
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00r2-0490000000-625959dcfd8994594374
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0290000000-5526f6982de2b835834d
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-4950000000-1c4dfcf0e92977f81b2d
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-006x-2930000000-794f35756758cdd0fd7e
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00kg-6930000000-a3311fa41a9960793a3c
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at May 20, 2019 15:08 / Updated at June 12, 2020 16:53